Systolic blood pressure as a predictor of pathologic mobility of kidney

For the purpose of influence studying the depending on a position of changes of the main venous blood-groove a kidney on systolic arterial pressure measurement of arterial pressure, blood-groove speed in renal veins is taken, resistance indexes among patients with pathological mobility of a kidney are defined. These researches showed dependence of systolic arterial pressure as from high-speed, and resistive indicators in both kidney vessels. It is shown that measurement of arterial pressure in six static states can give a new modern assessment to physiological norm of arterial pressure and help with diagnostics of the early pathogenetic factors responsible for development of arterial hypertension

FUNCTIONAL BEAM RESEARCH METHODS IN THE DIAGNOSIS OF ABNORMAL MOBILITY OF KIDNEY

Abstract:Introduction. Abnormal mobility of kidney - a combination nephroptosis with abnormal rotation in one or more static state. The main beam is at present diagnostic methods. Only ultrasound has the functionality, the ability to use polypositional.The purpose of the study. Development of functional radiological methods of diagnosis of pathological mobility of the kidney and its complications.Research methods. The methods of determining the angle of rotation according to the kidney excretory urography performed in wedge and orthostasis, ultrasound sonography, Doppler, dynamic indirect kidney scan and computed tomography. Statistical processing of the data using the package STATISTICA 6.0 software licensing and computer programs, correlation analysis, frequency and multiple correspondence analysis.The main results. To determine the location of each case properly distributed in accordance with the classification matrices further method was used polypositional ultrasound, which allowed to determine the position of the patient, which revealed significant correlated with the RMS, hemoand urodynamic changes. Application rentgenradiological diagnostic methods in the corresponding position of the fixed kidney complications pathological mobility.The main conclusions. The combination of ultrasonic, radiographic, radioisotope diagnostic PMK and its complications allows us to supplement the information content of these studies and to expand the diagnostic value of each of them. An integrated approach to the implementation of diagnostic tests will improve the efficiency of the treatment of complications PMK, reduce material costs, which in turn will improve the quality of treatment of patients with this pathology

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic. The well-known interindividual variability of T2D drug actions such as biguanides, sulfonylureas/meglitinides, DPP-4 inhibitors/GLP1R agonists and SGLT-2 inhibitors may be caused, among other things, by genetic factors. Pharmacogenetic findings may aid in identifying new drug targets and obtaining in-depth knowledge of the causes of disease and its physiological processes, thereby, providing an opportunity to elaborate an algorithm for tailor or precision treatment. The aim of this article is to summarize recent progress and discoveries for T2D pharmacogenetics and to discuss the factors which limit the furthering accumulation of genetic variability knowledge in patient response to therapy that will allow improvement the personalized treatment of T2D

Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus

Metformin is an oral hypoglycemic agent widely used in clinical practice for treatment of patients with type 2 diabetes mellitus (T2DM). The wide interindividual variability of response to metformin therapy was shown, and recently the impact of several genetic variants was reported. To assess the independent and combined effect of the genetic polymorphism on glycemic response to metformin, we performed an association analysis of the variants in ATM, SLC22A1, SLC47A1, and SLC2A2 genes with metformin response in 299 patients with T2DM. Likewise, the distribution of allele and genotype frequencies of the studied gene variants was analyzed in an extended group of patients with T2DM (n = 464) and a population group (n = 129). According to our results, one variant, rs12208357 in the SLC22A1 gene, had a significant impact on response to metformin in T2DM patients. Carriers of TT genotype and T allele had a lower response to metformin compared to carriers of CC/CT genotypes and C allele (p-value = 0.0246, p-value = 0.0059, respectively). To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics. The model based on a set of four parameters, including gender, rs12208357 genotype, familial T2DM background, and waist–hip ratio (WHR) showed the highest prediction accuracy for the response to metformin therapy in patients with T2DM (AUC = 0.62 in cross-validation). Further pharmacogenetic studies may aid in the discovery of the fundamental mechanisms of type 2 diabetes, the identification of new drug targets, and finally, it could advance the development of personalized treatment